GlassScriptPhysician profile
Jason Mckinney
NPI 1225219306
$6,025.00
in general payments reported to CMS, 2019-2025
27 companies · $909 in 2025
The $909 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $303 · 2021: $888 · 2022: $803 · 2023: $1,694 · 2024: $832 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601 · Travel and Lodging: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,600.54 |
| Travel and Lodging | $833.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,313.55 | 2019-2025 | |
| Zimvie INC. | $833.38 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $732.14 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $617.00 | 2019-2025 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $466.52 | 2019-2025 | |
| Gilead Sciences, INC. | $210.99 | 2020-2025 | |
| Celgene Corporation | $159.98 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $100.59 | 2021-2023 | Rebyota |
| Madrigal Pharmaceuticals | $79.41 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $68.60 | 2019-2021 | |
| Braintree Laboratories, INC. | $44.02 | 2020-2022 | |
| Evoke Pharma, INC. | $36.66 | 2021-2022 | |
| Genzyme Corporation | $35.96 | 2023-2024 | |
| Conmed Corporation | $35.77 | 2024 | System 2450 |
| Aimmune Therapeutics, INC. | $34.09 | 2024-2025 | Zenpep |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $32.50 | 2025 | |
| Ardelyx, INC. | $31.73 | 2022-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $31.31 | 2020-2023 | Ocaliva |
| Mauna Kea Technologies, INC. | $29.99 | 2024 | |
| Boston Scientific Corporation | $26.97 | 2020-2023 | |
| Baxter Healthcare | $21.76 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Lilly USA, LLC | $18.89 | 2025 | Omvoh |
| Qol Medical, LLC | $16.17 | 2021 | |
| Ucb, INC. | $15.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.94 | 2023 | Cyltezo |
| Romark Laboratories, Lc | $13.66 | 2019 | |
| Phathom Pharmaceuticals, INC. | $3.80 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Mckinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.